Richen Europe

What Richen Europe does

Richen Europe S.r.l. is an Italian pharmaceutical company founded in 2014 and headquartered in Trezzano Sul Naviglio (Milan), operating as the European subsidiary of the Richen Medical Science Group, whose Chinese parent is Beijing Richen Force Science & Technology Co., Ltd. The company manufactures medical diagnostic products and medical instrumentation focused on gastroenterology, serving hospitals, clinical laboratories, and gastroenterology departments across European markets with a stated base of approximately 285 international clients and 13 gastroenterology products. The group is led by Managing Director Dr. Attilio Citrino, who also serves as data controller.

Its product portfolio is organized across two core lines plus a COVID-19 product line. The Medical Instrumentation line includes the IR-Force infrared spectrometer family (Series 200, 300, 500, 600) for C13 Urea Breath Test (UBT) analysis and the Lactotest 102 and 202 H2 breath test monitors that use electrochemical hydrogen sensors with optional methane (CH4) and carbon dioxide (CO2) detection via infrared analyzers. The Medical Diagnostic line comprises consumable kits: Citredici (C13 UBT), LactoBreath and GlucoBreath (H2 breath tests for lactose intolerance and SIBO), the BIO Fast HD ultra-rapid urease test for H. pylori biopsy detection using bromothymol blue, and the Helic Kit HPSA fecal antigen immunochromatographic rapid test. The COVID-19 line adds TAYHAMN FFP2 masks and SARS-CoV-2 rapid antigen (~97.67% reliability) and serological (~99.1% reliability) tests. Instruments are paired with PDI (Patient Data Interface) software for workflow integration.

Revenue is generated through one-time hardware sales of medical instruments plus recurring sales of consumable diagnostic kits. Pricing is not publicly disclosed and is handled through gated contact and registration forms. Distribution combines an internal field sales force with regional external sales agents in Italy (active recruitment across Piemonte, Liguria, and Emilia Romagna), broader European export activity, and, as of April 2024, an exclusive channel partnership with ITC Farma Srl covering the Breath Test sector. The company operates with approximately 25 professional employees and runs the Richen Group Open Competition research program in conjunction with the European Helicobacter & Microbiota Study Group (EHMSG), where it has maintained sponsorship since 2015.

Name

Richen Europe

Legal name

Richen Europe S.r.l.

Website

https://richeneurope.eu

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Richen Europe is an Italian pharmaceutical subsidiary of the Richen Medical Science Group that designs, manufactures, and distributes gastroenterology diagnostic instruments and consumables, including infrared spectrometers, H2 breath monitors, and H. pylori rapid tests, for hospitals and laboratories across Europe.

Ownership category

akta.pro rank

Product category

Gastroenterology Medical Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Gastroenterology diagnostics
• Breath test devices
• Medical instrumentation
• Helicobacter pylori testing
• Rapid diagnostic tests

Headquarters

HQ city

Trezzano Sul Naviglio

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Diagnostic Products: Richen Europe manufactures and sells medical diagnostic products including C13 Breath Test kits (Citredici), H2 Breath Test kits (LactoBreath, GlucoBreath), rapid tests (Helic Kit HPSA, BIO Fast HD), and COVID-19 diagnostic products. These are sold to hospitals, laboratories, and clinics across Europe.
2. Medical Instrumentation: Sale of medical instruments including infrared spectrometers (IR-Force series) and H2 breath test monitors (Lactotest 102, Lactotest 202). Products are sold with associated software (PDI - Patient Data Interface) for data management and hospital system integration.
3. COVID-19 Products: Sale of FFP2 masks (TAYHAMN brand) and SARS-CoV-2 rapid tests during the pandemic period.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Richen Europe manufactures and sells medical diagnostic kits and medical instruments focused on the gastroenterology field. Its portfolio covers C13 Urea Breath Test kits and infrared spectrometers, H2 Breath Test kits and Lactotest hydrogen/methane monitors for lactose intolerance and SIBO diagnosis, immunochromatographic rapid tests for H. pylori and SARS-CoV-2 detection, an ultra-rapid urease test (BIO Fast HD), and a line of COVID-19 products (FFP2 masks, rapid antigen and serological tests). The products are sold to hospitals, clinical laboratories, gastroenterology departments, and medical distributors across European markets.

Product overview

Richen Europe offers a comprehensive portfolio of medical diagnostic products and medical instrumentation focused on gastroenterology, comprising two main product lines. The Medical Instrumentation line includes the Infrared Spectrometer series (200, 300, 500, 600) for C13 Urea Breath Test analysis using infrared technology, and the Lactotest H2 Breath Test monitors (102, 202) featuring electrochemical sensors for hydrogen, methane, and carbon dioxide detection. The Medical Diagnostic line comprises diagnostic kits including Citredici Urea Breath Test KIT, LactoBreath and GlucoBreath H2 Breath Test kits, BIO Fast HD rapid urease test, and Helic Kit HPSA rapid antigen test for Helicobacter pylori detection. Additionally, the company offers Covid-19 products including FFP2 masks, rapid antigen tests, and rapid serological tests for IgM/IgG antibodies. The portfolio is designed for use in gastroenterology practices, hospitals, and diagnostic laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• Richen Medical Science Group: Parent group encompassing Richen Europe and Beijing Richen Force Science & Technology Co, Ltd

Products and services

• Citredici Urea Breath Test KIT Urea Breath Test kit for C13 breath test diagnosis used for the non-invasive detection of Helicobacter pylori infection; intended for hospitals, clinical laboratories, and gastroenterology departments.
• LactoBreath H2 Breath Test kit for diagnosis of lactose malabsorption or intolerance; includes lactose substrate and breath collection bags for use by clinical laboratories and gastroenterology departments.
• GlucoBreath H2 Breath Test kit for determination of bacterial intestinal contamination (SIBO diagnosis); includes glucose substrate and breath collection bags for clinical laboratories and gastroenterology departments.
• BIO Fast HD Ultra-rapid urease test for research and determination of Helicobacter pylori bacterial count during gastroscopy; uses bromothymol blue indicator for pH-based color change detection with 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes, retaining sensitivity under PPI therapy.
• Helic Kit - HPSA Immunochromatographic rapid test card for qualitative determination of Helicobacter pylori antigen in human fecal samples, providing non-invasive screening with high precision for hospitals and laboratories.
• Lactotest 102 Hydrogen Breath Test monitor for rapid and reliable diagnosis of gastrointestinal disorders; features an electrochemical H2 sensor with thermal compensation, weekly calibration, and PDI software integration for hospital information system connectivity.
• Lactotest 202 Hydrogen, methane, and carbon dioxide Breath Test monitor available in Control (H2+CO2) and Xtend (H2+CO2+CH4) variants; uses an electrochemical H2 sensor and infrared analyzers for CH4 and CO2 detection in gastroenterology diagnostics.
• Infrared Spectrometer Series 200 Infrared spectrometer instrument for C13 Urea Breath Test analysis; entry-level compact analyzer used by clinical laboratories and gastroenterology departments for H. pylori detection.
• Infrared Spectrometer Series 300 Infrared spectrometer instrument for C13 Urea Breath Test analysis; mid-range analyzer for clinical laboratories performing H. pylori diagnostics.
• Infrared Spectrometer Series 500 Integrated infrared system for C13 Urea Breath Test analysis; fully integrated analyzer for high-volume clinical laboratory use in H. pylori detection workflows.
• Infrared Spectrometer Series 600 Infrared spectrometer for C13 Urea Breath Test analysis; high-end analyzer in the IR-Force line used in clinical laboratories for H. pylori diagnostics.
• FFP2 Mask (TAYHAMN) Single-use FFP2 protective mask without valve, featuring conformable nose clip and ear loops, compliant with EN149-2001+A1-2009; supplied in packs of 50 for healthcare facilities.
• SARS-COV-2 Rapid Antigen Test Rapid antigen test using nasopharyngeal, nasal, or oral-faryngeal swab for direct detection of SARS-CoV-2 virus antigens; results in 10–60 minutes with approximately 97.67% reliability for healthcare providers.
• SARS-COV-2 Rapid Serological Test Rapid serological test for detection of IgM/IgG antibodies against SARS-CoV-2 using immunochromatography on capillary blood samples; results in 10 minutes with approximately 99.1% reliability for healthcare providers.

Quantifiable outcome

• BIO Fast HD urease test achieves 100% specificity and 100% sensitivity for high-moderate bacterial count after 5 minutes
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• European Helicobacter & Microbiota Study Group (EHMSG)coreStrategic or Co-development Partner · 12 September 2024Richen Europe participated as Industry Partner at the 37th EHMSG Workshop in Porto, Portugal, September 2024. The workshop is part of United European Gastroenterology.
• ITC Farma SrlcoreChannel Partner/ Reseller/ Distributor · 3 April 2024Exclusive concession agreement signed with ITC Farma Srl in April 2024 for the Breath Test sector. The partnership combines Richen Europe's experience in breath test technology with ITC Farma's research and market expertise, marking a new challenge in the Breath Test sector. Announced at the 30th FISMAD Congress in Rome.
• SAIL in BhutanminorStrategic or Co-development Partner · 1 January 2018Partnership supporting H. pylori eradication efforts in Bhutan, where infection rates reach 90% compared to 50% global average. The partnership aims to save lives from gastric cancer through H. pylori eradication, supporting the SAIL (Stool-based Antigens for Infant and Leptospirosis?) initiative.
• European Helicobacter & Microbiota Study Group (EHMSG)coreStrategic or Co-development Partner · 1 January 2015Since 2015, Richen Group has been supporting EHMSG as Platinum Sponsor (some sources indicate Gold Sponsor status). EHMSG is a multidisciplinary group founded in 1987, composed of representatives from most EU countries, organizing annual workshops on Helicobacter and microbiota research. Richen also runs research competitions (Open Competitions) for early-career researchers in partnership with EHMSG.
• Beijing Richen Force Science & Technology Co, LtdcoreTechnology or IntegrationParent company and core technology partner within the Richen Medical Science Group. Part of the Richen Group structure, providing technological and manufacturing capabilities for the European subsidiary.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Biohit Oyj: Finnish diagnostics company specializing in H. pylori and gastrointestinal diagnostics, including the GastroPanel blood-test panel and UBT products. Directly competes with Richen Europe in the gastroenterology diagnostic market across European hospital and lab channels.
• Commonwealth Diagnostics & Sciences (Gemelli Biotech): US-based specialty GI diagnostics company offering hydrogen/methane breath testing for SIBO, IMO and lactose intolerance - directly comparable to Richen Europe's Lactotest H2/CH4/CO2 breath-test platform and GlucoBreath/LactoBreath kits. Both target the same gastroenterology use cases with non-invasive breath-based diagnostics.
• Mayoly Spindler: French privately-held pharmaceutical company with a gastroenterology-focused portfolio including urea breath test (Kibion Dynamic) products. Directly comparable to Richen Europe as a specialty GI pharma and diagnostics player with European distribution.

Broad incumbents

• EUROIMMUN (Revvity/PerkinElmer): Major European diagnostics manufacturer (now under Revvity) producing immunoassay reagents and automated analyzer systems for infectious disease and gastroenterology, including H. pylori serology. Larger-scale incumbent whose automated immunoassay platforms compete with Richen's specialized breath-test workflow.
• Cosmo Pharmaceuticals: European specialty pharmaceutical company with a strong gastroenterology franchise (Aemcolo/ rifamycin, GI delivery technologies, and diagnostic devices). Comparable in its GI-specialist commercial focus but materially larger and publicly listed, with broader portfolio and balance sheet.
• Meridian Bioscience (Revvity): US-headquartered diagnostics company (now part of Revvity) with a leading gastroenterology product line including H. pylori stool antigen tests, Premier UBT platform, and C. difficile assays. Overlaps with Richen Europe's UBT and H. pylori antigen test portfolio but at much larger scale and global footprint.
• Otsuka Holdings (Otsuka Pharmaceutical): Japanese pharmaceutical group with gastroenterology and H. pylori eradication therapy franchise (e.g., Pylera, vonoprazan-based regimens). Larger incumbent operating in the same downstream H. pylori care pathway that Richen Europe's diagnostic products feed into.
• Abbott Diagnostics: Global IVD leader with H. pylori serology and breath-test products (formerly Axis-Shield UBT) and broad hospital lab menu. Represents the large multinational competitor set that Richen Europe is differentiated against on specialty GI focus and clinical workflow integration.

Regional players

• Alfa Wassermann: Italian pharmaceutical and diagnostics company headquartered near Bologna, with divisions covering clinical chemistry, gastroenterology and hospital diagnostics. Regional European peer with comparable geography (Italy) and overlapping hospital lab customer base, though broader in therapeutic areas than Richen Europe's GI-only focus.

Emerging players

• AB Biotics: Spanish biotech focused on microbiome-based diagnostics and probiotics, with H. pylori and gut-health products. Comparable emerging European player addressing overlapping gastroenterology/microbiota use cases (e.g., H. pylori eradication, SIBO), but at smaller scale and more research-stage.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/richen-europe
• Xx.com/richeneurope
• Facebookfacebook.com/richeneurope

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Richen Europe